Abstract #0057

Multiparametric MRI signatures of immune response in patients with HER2+ breast cancer treated with trastuzumab

Bonny Chau¹, Debosmita Biswas¹, Anum S. Kazerouni¹, Daniel S. Hippe¹, Rebeca Alvarez¹, Suzanne Dintzis¹, Laura C. Kennedy², Vijayakrishna Gadi³, and Savannah C. Partridge ¹

¹University of Washington, Seattle, WA, United States, ²Vanderbilt University, Nashville, TN, United States, ³University of Illinois, Chicago, IL, United States

We investigated the relationship between immune infiltration and imaging metrics derived from breast MRI in patients with HER2+ breast cancer treated with trastuzumab. Fourteen patients with localized HER2+ breast cancer were imaged with diffusion-weighted and dynamic contrast-enhanced (DCE-) MRI prior to and ~2 weeks after a run-in dose of trastuzumab. Pre-treatment ADC and change in DCE-MRI peak percent enhancement were both significantly associated with immune response as characterized by change in level of tumor infiltrating lymphocytes.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.